Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q2 2020 · 10-Q
Revenue$126.73M$126.73M+21.0% vs Q2 2019 Net Income$34.67M$34.67M+5.9% vs Q2 2019 EPS Diluted$0.65$0.65+6.6% vs Q2 2019 Operating Income$45,548,000+6.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$91,416,000+218.9% Margins · derivedOperating margin35.9%−4.7 pt vs Q2 2019
Net margin27.4%−3.9 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 17, 2020 · 48 d after period end